EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study

Roberto Gomeni, Françoise Bressolle-Gomeni

The Journal of Clinical Pharmacology · 2026-03 · 66 (3)

DOI: 10.1002/jcph.70174 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 06.03.2026. Verfasst von Roberto Gomeni und 1 weiteren Autor:innen. Beteiligte Einrichtung: R&D Department, PharmacoMetrica, Lieu-dit Longcol, La Fouillade, France. Hauptthemen laut MEDLINE: Deep Learning, Models, Biological, Drug Development, Warfarin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐informed drug development (MIDD) has traditionally been guided by hypothesis‐driven modeling, in which models are constructed based on established biological mechanisms, physicochemical principles, and experimental hypotheses. More recently, the rise of artificial intelligence has enabled data‐driven modeling approaches that often bypass explicit mechanistic assumptions. The potential synergy between these two paradigms is reshaping strategies for implementing MIDD. This study aims to compare deep‐learning‐driven and hypothesis‐driven approaches, highlighting their respective strengths, limitations, and opportunities for integration. A case study is presented with the re‐analysis of warfarin PK and PK/PD using both modeling paradigms. The comparative PK analysis indicated that the deep‐learning model achieved predictive performance comparable to, and numerically slightly better than, hypothesis‐driven modeling based on a one‐compartment PK model. The hypothesis‐based PK/PD analysis was conducted using three model structures: direct effect, effect compartment, and indirect response. The results of these analyses, including the estimated clinical dose, were compared with those obtained from the deep‐learning approach. The deep‐learning model demonstrated predictive performance similar to that of the effect compartment and indirect response models and yielded a comparable estimate of the effective dose across the two modeling approaches. A simulation‐based sensitivity analysis was conducted to evaluate the robustness of the dose selection derived from the deep‐learning‐based modeling approach. The outcomes of the analysis suggest that effective implementation of the MIDD paradigm may be enhanced through the complementary use of deep‐learning‐based approaches alongside established hypothesis‐driven, mechanistic models, thereby supporting evidence‐based drug development and regulatory decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep LearningModels, BiologicalDrug DevelopmentWarfarinHumansPredictive Learning Models

Stichwörter der Autor:innen

artificial intelligencedeep learningdose selectionhypothesis drivenmodel‐informed drug development

Substanzen

Warfarin

Autor:innen und Institutionen

  • R&D Department, PharmacoMetrica, Lieu-dit Longcol, La Fouillade, France.

Zitieren

APA

Gomeni, R., & Bressolle-Gomeni, F. (2026). Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study. The Journal of Clinical Pharmacology, 66(3). https://doi.org/10.1002/jcph.70174

Vancouver

Gomeni R, Bressolle-Gomeni F. Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study. The Journal of Clinical Pharmacology. 2026;66(3). doi:10.1002/jcph.70174

BibTeX
@article{Gomeni2026,
  author = {Gomeni, Roberto and Bressolle-Gomeni, Françoise},
  title = {Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {3},
  doi = {10.1002/jcph.70174}
}
Kostenlos starten →